Diabetes Update- Pharmacist

  Price  

  Credits  1.5

This product is currently out of stock and unavailable.


Format
The prevalence of diabetes mellitus (DM) in U.S. adults nearly doubled between 1995 and 2010, increasing from 4.5% to 8.2%. While researchers note that this dramatic increase is partly accounted for by people living longer with diabetes, the high prevalence is a significant public health issue. An estimated 11% of adults aged 20 years or older have diabetes. Among those aged 65 years or older, the prevalence is much higher – an estimated 27%. Perhaps most alarming is the rise among U.S. adolescents: the prevalence of prediabetes and diabetes in the 12 - 19 year age group increased from 9% in 1999 to 23% in 2008. A boom in diabetes research over the last decade has generated new insights and considerations in diabetes management. The number of available medications with different mechanisms of action, while welcome, has complicated treatment choices. And more medications are sure to follow – a 2012 pharmaceutical manufacturer report listed 221 drugs in the pipeline for diabetes and diabetes-related conditions. This issue will discuss recent developments in diabetes, including significant changes in adult practice guidelines, the establishment of pediatric guidelines, and medication updates: angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) for the management of diabetic kidney disease, a new DPP-4 inhibitor (alogliptin), a first-in-class sodium-glucose co-transporter 2 (SGLT2) inhibitor (canagliflozin [Invokana™]), and an investigational, ultra-long-acting insulin.

OR

Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Pharm/Nurse Drug Therapy

Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

Course Accreditation

  • Activity Type:
    Knowledge
  • CE Broker
  • Universal Activity Number:
    Pharmacist : 0428-0000-13-005-H01-P
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.